In re Effexor XR Antitrust Litigation

Citation Number: 3:11-cv-05479
Federal Court: District of New Jersey

Brief of the Federal Trade Commission as amicus curiae before the United States District Court for the District of New Jersey, addressing the question of whether a branded company's commitment not to launch an authorized generic in competition with a generic company constitutes a payment-for-delay in restraint of trade, pursuant to the Third Circuit's ruling in In re K-Dur Antitrust Litigation, No. 10-2077, 2012 WL 2877662 (3d Cir. July 16, 2012).